Related Experiment Video
Updated: Jun 7, 2026
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
Predicting cognitive decline in Alzheimer's disease: an integrated analysis
Oscar L Lopez1, Elias Schwam, Jeffrey Cummings
1Department of Neurology, Alzheimer's Disease Research Center, University of Pittsburgh, Pittsburgh, PA, USA. lopezol@upmc.edu
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|November 4, 2010
Summary
Alzheimer's disease patients with younger age and severe symptoms decline faster. Donepezil treatment significantly reduced the risk of rapid cognitive decline in Alzheimer's patients.
Area of Science:
- Neurology
- Pharmacology
- Gerontology
Background:
- Alzheimer's disease (AD) is characterized by rapid cognitive decline influenced by patient and disease factors.
- The impact of pharmacological interventions on mitigating this decline is not well-defined.
Purpose of the Study:
- To identify predictors of rapid cognitive decline in Alzheimer's disease patients.
- To evaluate the effect of donepezil on reducing the risk of fast cognitive decline.
Main Methods:
- Pooled data from 14 randomized clinical trials of donepezil in AD treatment (N=3748).
- Analysis of predictors for fast decline and donepezil's effect on this risk.
Main Results:
- Younger age and more severe baseline cognitive, global, or behavioral status predicted faster decline in placebo groups.
- Donepezil treatment showed a 39% to 63% reduction in the risk of rapid decline.
Conclusions:
- Age and baseline disease severity are linked to cognitive decline rates in AD.
- Symptomatic therapies like donepezil may decrease the likelihood of faster cognitive decline in treated individuals.
Related Concept Videos
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:30Cognitive Development During Adulthood
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...